Impact of Switch to Fosamprenavir and Addition of Lovaza® for Treatment of Hypertriglyceridemia in HIV-Infected Subjects on Antiretroviral Therapy

Autor:	Belinda Ha, Anthony Scarsella, Keith A. Pappa, Homayoon Khanlou, Winston Young, Henry Zhao, Franco Felizarta, Lisa Ross
Rok vydání:	2012
Předmět:	Drug Triglyceride business.industry media_common.quotation_subject Hypertriglyceridemia Fosamprenavir Pharmacology Fish oil medicine.disease chemistry.chemical_compound chemistry medicine Protease inhibitor (pharmacology) Ritonavir Adverse effect business media_common medicine.drug
Zdroj:	World Journal of AIDS. :24-32
ISSN:	2160-8822 2160-8814
DOI:	10.4236/wja.2012.21004
Popis:	Background: Managing hypertriglyceridemia in HIV-infected patients often requires multiple pharmacologic strategies. Many protease inhibitors (PIs), one of 6 classes of drugs used to treat HIV, have been associated with hypercholesterolemia and drug interactions. For this study, we examined a dual strategy to manage hypertriglyceridemia in HIV-infected patient taking PIs: 1) switching patients to fosamprenavir (FPV), a PI with fewer drug interactions, and 2) adding prescription fish oil (LOVAZA(R)), which has been shown to reduce triglycerides. Methods: This multicenter, 24-week study enrolled 36 patients virologically suppressed (HIV-1 RNA
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d8e50a2c2b0fccab54b968d4f7e667e0 https://doi.org/10.4236/wja.2012.21004 Zobrazit plný text záznamu